Metastatic renal cell carcinoma is an incurable cancer. Gain in progression-free survival with new drugs is around 3 months. Patient-reported outcomes are an essential endpoint with strong impact on clinical benefit. The quality of the methodology and the data analysis of patient-reported outcomes are not yet optimal. New-generation therapies should demonstrate not only a gain in survival but also in quality of life.